Experimental drug combo targets tough lung cancer
NCT ID NCT01118676
First seen Apr 18, 2026 · Last updated May 30, 2026 · Updated 5 times
Summary
This early-phase trial tested the safety of adding an experimental drug called cilengitide to standard chemotherapy and radiation for people with locally advanced non-small cell lung cancer. Fourteen patients received the drug continuously along with their usual treatment. The main goal was to find the highest safe dose and see how well the combination worked.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Toulouse Larrey
Toulouse, 31000, France
-
Institut Claudius Regaud
Toulouse, 31000, France
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.